This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Linseman, J. V. Articles by Bristow, M. R. Search for Related Content PubMed PubMed Citation Articles by Linseman, J. V. Articles by Bristow, M. R. Related Collections Congestive Secondary prevention Related Article

(Circulation. 2003;107:1234.)
© 2003 American Heart Association, Inc.

Editorial

Drug Therapy and Heart Failure Prevention

Jennifer V. Linseman, PhD; Michael R. Bristow, MD, PhD

From the Division of Cardiology, University of Colorado Health Sciences Center, Denver, Colo.

Correspondence to Michael R. Bristow, MD, PhD, Division of Cardiology, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Denver CO 80262.

Key Words: Key Words: • Editorials • drugs • heart failure • prevention • trials

An extract of the first 250 words of the full text is provided, because this article has no abstract.

There are at least 5 million people in the United States living with chronic heart failure (CHF) today.¹ Approximately 550 000 new cases of heart failure are identified in this country each year.¹ In addition, there are tens of millions more people living with one or more risk factors for the development of heart failure, including coronary artery disease, hypertension, dyslipidemia, obesity, and diabetes, and these numbers are presently on the rise. Clinical research conducted over the last decade has focused primarily on enhancing treatment options for patients with known left ventricular (LV) dysfunction, with or without heart failure symptoms. Thanks to the treatments identified by such studies as Studies of Left Ventricular Dysfunction (SOLVD),² Randomized Aldactone Evaluation Study (RALES),³ The Cardiac Insufficiency Bisoprolol Study II (CIBIS II),⁴ Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF),⁵ Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS),⁶ and many others, the risk of morbidity and mortality after heart failure diagnosis has been substantially lowered, provided that patients with CHF are actually treated with inhibitors of the renin-angiotensin-aldosterone system and ß-blockers. In contrast, very little is known about what interventions can be utilized to improve and/or prolong the lives of the much larger and broader group of patients mentioned above, who are at risk of developing left ventricular dysfunction and CHF. Aside from appropriately treating prevailing conditions, what else, if anything, can be done to impact the future health status of these at-risk patients?

See p 1284

The first trial to prospectively examine this . . . [Full Text of this Article]

Related Article:

Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study

J. Malcolm O. Arnold, Salim Yusuf, James Young, James Mathew, David Johnstone, Alvaro Avezum, Eva Lonn, Janice Pogue, Jackie Bosch on behalf of the HOPE Investigators
Circulation 2003 107: 1284-1290. [Abstract] [Full Text]

This article has been cited by other articles:

				M. Bourraindeloup, C. Adamy, G. Candiani, M. Cailleret, M.-C. Bourin, T. Badoual, J. B. Su, S. Adubeiro, F. Roudot-Thoraval, J.-L. Dubois-Rande, et al. N-Acetylcysteine Treatment Normalizes Serum Tumor Necrosis Factor-{alpha} Level and Hinders the Progression of Cardiac Injury in Hypertensive Rats Circulation, October 5, 2004; 110(14): 2003 - 2009. [Abstract] [Full Text] [PDF]

				H. J.J. Wellens Cardiac arrhythmias: The quest for a cure: A historical perspective J. Am. Coll. Cardiol., September 15, 2004; 44(6): 1155 - 1163. [Abstract] [Full Text] [PDF]

				H Weber, K Allikmets, and G Kornfeld Treating electrical instability in sudden cardiac death survivors - are we looking at the right side of the coin? Eur. Heart J., April 2, 2004; 25(8): 623 - 625. [Full Text] [PDF]

				M. Metra, S. Nodari, and L. Dei Cas Current guidelines in the pharmacological management of chronic heart failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1_suppl): S11 - S16. [Abstract] [PDF]